메뉴 건너뛰기




Volumn 91, Issue 4, 2012, Pages 643-644

Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENDAMUSTINE; FLUORODEOXYGLUCOSE; GANCICLOVIR; RITUXIMAB; VALGANCICLOVIR; VIRUS ANTIGEN; ALKYLATING AGENT; CHLORMETHINE DERIVATIVE;

EID: 84860825448     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1307-z     Document Type: Letter
Times cited : (24)

References (5)
  • 1
    • 20644469242 scopus 로고    scopus 로고
    • Bendamustine plus rituximab is effective and has favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
    • Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus rituximab is effective and has favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389
    • (2005) J Clin Oncol , vol.23 , pp. 3383-3389
    • Rummel, M.J.1    Al-Batran, S.E.2    Kim, S.Z.3
  • 2
    • 52649177173 scopus 로고    scopus 로고
    • Phase II multicenter study of bendamustine plus rituximab in patients with relapsed B-cell and mantle cell non-Hodgkin's lymphoma
    • Robinson KS, Williams ME, van der Jagt RH et al (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 26:4473-4479
    • (2008) J Clin Oncol , vol.26 , pp. 4473-4479
    • Robinson, K.S.1    Williams, M.E.2    Van Der Jagt, R.H.3
  • 3
    • 77950488976 scopus 로고    scopus 로고
    • Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphoma: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphoma, Germany)
    • Rummel MJ, Niederle N, Maschmeyer G et al (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphoma: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphoma, Germany). Blood 114:168-169
    • (2009) Blood , vol.114 , pp. 168-169
    • Rummel, M.J.1    Niederle, N.2    Maschmeyer, G.3
  • 4
    • 74549225036 scopus 로고    scopus 로고
    • Bendamustine is effective therapy in patients with rituximab-refractory, indolent Bcell non-Hodgkin's lymphoma: Results from a multicenter study
    • Kahl BS, Bartlett NL, Leonard JP et al (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent Bcell non-Hodgkin's lymphoma: results from a multicenter study. Cancer 116:106-114
    • (2010) Cancer , vol.116 , pp. 106-114
    • Kahl, B.S.1    Bartlett, N.L.2    Leonard, J.P.3
  • 5
    • 0028104691 scopus 로고
    • Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia
    • Maung ZT, Wood AC, Jackson GH, Turner GE, Appleton AL, Hamilton PJ (1994) Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 88:649-652
    • (1994) Br J Haematol , vol.88 , pp. 649-652
    • Maung, Z.T.1    Wood, A.C.2    Jackson, G.H.3    Turner, G.E.4    Appleton, A.L.5    Hamilton, P.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.